Requests for award are now open for the developjment of cancer-related programs.
The purpose of this RFA is to stimulate the development of high-quality, program project grants that will move forward to nationally-funded grant awards.
Thematic proposals are suggested provided they maintain a clear cancer focus. Projects with translational potential are encouraged, but not mandatory.
Penn State Cancer Institute leadership anticipates distributing four awards at $150,000 for one year. If project milestones are completed in a timely manner, additional funding for the project may be available.
Applications are due 5 p.m. Aug. 3, 2018.
Jump to topic
Development of Cancer-Related Program Project Grants
Principal Investigators are required to be members of the Penn State Cancer Institute.
Project budgets may only support Penn State faculty members. Non-Penn State Cancer Institute investigators should be encouraged to apply for membership. Project leader eligibility should be consistent with the current NCI eligibility rules for P01 project leaders.
- Funds will be awarded on a competitive basis for a maximum of $150,000.
- The maximum period of award is 12 months.
- Awardees are required to submit brief quarterly progress reports, a final progress report upon project completion and updates to this report for 5 years post award.
- If timely progress is not made throughout the award year and funds have not been fully expended by the end of the project period, the funds will be returned to the Cancer Institute.
- Principal Investigators are expected to seek regulatory approvals in a timely manner because project periods will not be extended.
- Note: funding cannot be released until all applicable human, animal and/or biohazard protocols have been approved and copies sent to Penn State Cancer Institute administrative office.
- Awards will be transferable from one principal investigator to another only in special circumstances as approved by Cancer Institute director. All publications derived from this funding must acknowledge cancer institute support.
This is a two-step process.
- Letter of Intent (two page limit) – due to Colleen Kelley by August 3, 2018
- Full proposal submission for those who are invited to submit based on evaluation of letter of intent.
Letter of Intent should include:
- Arial 11 font and 0.5” margins
- Preliminary title
- Brief outline of the study plan for three-five projects (goal, hypothesis, specific aims, study methods, impact)
- List two-three potential shared resources that will be utilized
- Complete list of the investigative team, academic title, primary departments and roles
- Biosketches and Other Support documentation for Principal Investigators and Project Leaders
All letters of intent will be reviewed by Penn State Cancer Institute associate directors with no conflicts of interest. Notifications and full application instructions will be sent by August 17, 2018.
Full application is due by September 28, 2018. Applications received by the deadline will be scientifically peer-reviewed by investigators with substantial expertise in the project area. Notifications of awards will be made December 1, 2018. The earliest anticipated start date is January 1, 2019 depending on the status of human, animal and/or biohazard protocol approvals.
Note: excessive delay on these approvals does not constitute justification for a no-cost extension.
If you're having trouble accessing this content, or would like it in another format, please email the Penn State College of Medicine web department.